Business ❯ Investing ❯ Manufacturing

Pharmaceuticals

Eli Lilly Novartis AstraZeneca Johnson & Johnson Obesity Medicines Respiratory Medicines Sterile Injectables Construction Sector Eli Lilly and Company Bioconjugate Drugs Drug Manufacturing Formulations Oncology and Neurological Diseases Biopharmaceuticals Active Pharmaceutical Ingredients Electric Vehicles Injectable Medicines

AbbVie to Build $1.4 Billion Injectable-Medicines Campus in Durham, N.C.

Performance-based incentives make public support contingent on verified hiring.

Eli Lilly Picks Lehigh Valley for $3.5 Billion Plant to Make Next-Gen Weight-Loss Drugs

Eli Lilly Picks Huntsville for $6 Billion API Plant to Supply Next-Gen Drugs

AstraZeneca Invests $2 Billion to Expand Maryland Biologics and Build New Clinical Site

AstraZeneca Breaks Ground on $4.5 Billion Virginia Plant With Expanded Cancer and Obesity Drug Production

Eli Lilly Picks Virginia for $5 Billion Bioconjugate Plant, First of Four New U.S. Sites

AbbVie to Build $195 Million API Facility in North Chicago